USP25 and cancer: In this study, we found that USP25 is overexpressed in a subset of cancers, leading to activation of the NHEJ pathway and decreased sensitivity to radiotherapy and chemotherapeutic drugs, USP25 may be a good therapeutic target in clinical application.